KalVista Pharmaceuticals Inc. recently announced the presentation of new data at the European Academy of Allergy and Clinical Immunology Congress 2025 in Glasgow, United Kingdom. The data focus on the efficacy of sebetralstat for the on-demand treatment of hereditary angioedema $(HAE)$ attacks among patients receiving long-term prophylaxis. The KONFIDENT-S study highlighted the challenges of adherence to long-term prophylaxis and the need for effective on-demand treatments. Results showed that oral sebetralstat provided rapid relief for breakthrough attacks, with a median time to symptom relief of 1.3 hours. These findings were presented at the congress, indicating the potential of sebetralstat as a complementary treatment to existing long-term prophylaxis options. Links to the presentations are available on the KalVista website under Publications.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.